Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of multiple cancers, but the majority of patients remain refractory due to impaired MHC-I expression. Although the combination
Inhibition patterns were taken from the double reciprocal plots of the inhibition experiments (Fig. 3). Simple inhibition patterns were confirmed from linear replots of the slopes or intercepts versus
